Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.
- Conditions
- Lung Neoplasms
- First Posted Date
- 2003-01-14
- Last Posted Date
- 2006-07-20
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00051506
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Charleston, South Carolina, United States
ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2003-01-14
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT00051493
SU5416 and Carboplatin to Treat Ovarian Cancer
- Conditions
- Fallopian Tube NeoplasmOvarian CancerPeritoneal Neoplasm
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT00006155
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors
- Conditions
- Brain NeoplasmsGliomaMedulloblastoma
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00001502
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2002-11-15
- Last Posted Date
- 2009-01-09
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Registration Number
- NCT00049790
- Locations
- 🇺🇸
Indiana Cancer Pavilion, Indiana University, Indianapolis, Indiana, United States
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.
- Conditions
- Carcinoma, Non-Small-Cell LungPulmonary NeoplasmsNeoplasms, Lung
- First Posted Date
- 2002-08-06
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00042679
rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin
- Conditions
- Neoplasms, Gynecologic
- Interventions
- First Posted Date
- 2002-05-27
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00038012
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2002-05-01
- Last Posted Date
- 2010-04-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT00034541
- Locations
- 🇺🇸
ImClone Investigational Site, Indianapolis, Indiana, United States
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung CancerNeoplasm MetastasisLung Cancer
- First Posted Date
- 2002-04-26
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 194
- Registration Number
- NCT00034346
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.